Texas Bank & Trust Co Purchases New Position in AstraZeneca PLC (NASDAQ:AZN)

Texas Bank & Trust Co purchased a new stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 16,022 shares of the company's stock, valued at approximately $1,050,000.

Several other institutional investors also recently bought and sold shares of AZN. Diversify Wealth Management LLC grew its holdings in AstraZeneca by 3.6% in the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company's stock valued at $295,000 after purchasing an additional 153 shares during the period. Ameritas Advisory Services LLC grew its holdings in AstraZeneca by 25.9% in the fourth quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company's stock valued at $622,000 after purchasing an additional 1,949 shares during the period. Oak Ridge Investments LLC grew its holdings in AstraZeneca by 5.4% in the fourth quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company's stock valued at $9,433,000 after purchasing an additional 7,341 shares during the period. Asio Capital LLC grew its holdings in AstraZeneca by 11.6% in the fourth quarter. Asio Capital LLC now owns 53,541 shares of the company's stock valued at $3,508,000 after purchasing an additional 5,569 shares during the period. Finally, ZWJ Investment Counsel Inc. grew its holdings in AstraZeneca by 11.4% in the fourth quarter. ZWJ Investment Counsel Inc. now owns 730,700 shares of the company's stock valued at $47,875,000 after purchasing an additional 74,529 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Trading Up 1.3%

Shares of AZN stock opened at $68.81 on Friday. The stock's fifty day moving average is $70.46 and its two-hundred day moving average is $69.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The firm has a market capitalization of $213.40 billion, a P/E ratio of 30.45, a PEG ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The business had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. During the same quarter in the previous year, the firm earned $2.06 EPS. The company's quarterly revenue was up 7.2% compared to the same quarter last year. Research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on AZN shares. Morgan Stanley started coverage on AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock. UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. Finally, BNP Paribas initiated coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, AstraZeneca presently has an average rating of "Buy" and an average target price of $88.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.